REGENXBIO Inc. has developed a unique NAV Technology Platform facilitating gene therapy development, licensing it to pharma partners including AbbVie and Nippon Shinyaku. Despite a 20% revenue growth in 2025, the company remains unprofitable with rising operating losses and negative cash flows due to clinical trial holds and FDA scrutiny of lead assets targeting MPS I and II. Cash reserves near $34 million at year-end suggest limited runway, emphasizing the importance of partnership milestones, regulatory approvals, and capital raises for sustaining operations. Licensing royalties and milestone revenues from collaborations represent key near-term growth drivers but remain subject to clinical progress and FDA decisions.